Apomorphine still looks faster than ropinirole for canine emesis

CURRENT BRIEF VERSION: A new head-to-head evidence base is sharpening the choice between apomorphine and ropinirole when a dog needs emesis induction. Apomorphine remains the familiar extra-label standard in many clinics, while ropinirole ophthalmic solution, marketed as Clevor, is the first FDA-approved emetic for dogs in the U.S. A 2025 emergency-setting study found IV apomorphine outperformed ropinirole eye drops on first-dose success, speed of emesis, and need for rescue antiemetics, while a separate 2025 crossover trial in healthy dogs found both drugs were highly effective overall, with apomorphine acting faster and ropinirole linked to more ocular redness and some protracted vomiting. VetGirl’s recent podcast highlights that the practical decision is no longer just “does it work,” but which product fits the patient, the timeline, and the clinic workflow best. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary teams handling toxin ingestions or foreign-material exposures, speed and predictability matter. The newer data suggest apomorphine may still be the stronger option when rapid decontamination is critical, especially in emergency settings, but ropinirole offers a labeled, needle-free alternative that can be easier to administer and stock. That tradeoff, labeled convenience versus faster onset and fewer prolonged vomiting events, is likely to shape protocol updates, staff training, and conversations with pet parents about expectations after treatment. It also connects directly to what happens next if vomiting needs to be controlled: Dechra’s newly approved Emeprev injectable maropitant, expected through major distributors in early 2026, is being positioned around the same workflow themes, with no refrigeration and less injection pain in dogs due to benzyl alcohol while providing a bioequivalent antiemetic option for dogs and cats. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more clinics to revisit emesis protocols as additional real-world data emerge on which dogs benefit most from ropinirole’s labeled ophthalmic route versus apomorphine’s faster emergency performance. Also watch how newer antiemetic products such as Emeprev influence post-emesis rescue planning and inventory decisions, especially in practices looking for easier storage and a potentially more comfortable injectable maropitant option. (pubmed.ncbi.nlm.nih.gov)